Australia · Delayed Price · Currency is AUD Microba Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Core clinical test volumes grew 90% year-on-year, with strong adoption in Australia and the UK, and a full transition to high-margin products. Operational efficiencies, AI integration, and positive sector clinical trial readouts position the business for break-even and potential upside from therapeutics deals.
-
Strong core test growth and disciplined cost management offset legacy product wind-down, with revenue up 42% year-on-year excluding discontinued products. On track for regional break-even and poised for clean revenue growth from Q3, with major clinical and partnering catalysts ahead.
Fiscal Year 2025
-
Record core test growth drove FY2025 revenue up 30% year-on-year to $15.67 million, with strong adoption in Australia and the UK. FY2026 targets over 24,000 core tests and regional breakeven, while therapeutics shift to deal-making with two catalysts expected before year-end.
-
Revenue guidance narrowed to AUD 15.4–16 million for FY, with over 145% core product growth and break-even targeted in Australia and the UK by FY2026. AUD 14.5 million was raised to fund expansion, leveraging key partnerships and a product-led growth strategy.
-
Core diagnostic test volumes surged 240% year-on-year, with record growth in Australia and the U.K. Landmark clinical results for MetaPanel in IBD and a major partnership were announced. The therapeutics business shifted to a capital-light, partnering model.
-
Quarterly revenue surged 102% year-over-year to AUD 4.43 million, with MetaXplore test sales in Australia up 195% and strong momentum in both diagnostics and therapeutics. Expansion in the UK and robust partnerships underpin a positive outlook for continued growth.
-
Revenue surged 239% year on year to AUD 3.65 million, driven by strong MetaXplore sales in Australia and a successful UK launch. Strategic hires and expanded sales force support continued growth, with robust cash reserves and advancing therapeutics pipeline.
Fiscal Year 2024
-
Revenue surged 123% year-over-year to AUD 12 million, driven by strong diagnostic test adoption and UK expansion. Therapeutic programs advanced, including a completed Phase 1 trial and a major autoimmune discovery milestone.